Pharvaris (PHVS) Stock
Clinical biotech developing oral treatments for rare diseases. Here's the price, business snapshot, and what's worth knowing about Pharvaris in September 2026.
Pharvaris NV (PHVS) is a clinical-stage biopharmaceutical company developing small‑molecule therapies for bradykinin‑mediated disorders such as hereditary angioedema (HAE). Investors should know it focuses on oral treatment candidates and early‑to‑mid stage clinical programmes, so value is driven mainly by trial outcomes, regulatory milestones and potential partnerships or licensing deals. The company’s market capitalisation is around $1.54bn, reflecting investor expectations for successful development but also the risks typical of clinical-stage biotech: trial setbacks, regulatory uncertainty and funding needs. Financial runway, data readouts and commercial strategy are key variables to watch. This summary is for educational purposes only and not personal financial advice; investors should assess their own circumstances, consider diversification and be aware that biotech stocks can be volatile and may lose value.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying PHARVARIS NV's stock with a target price of $48.22, indicating growth potential.
Financial Health
Pharvaris NV shows strong financial performance with healthy cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Oral therapy focus
Developing oral small‑molecule candidates may expand patient convenience and market reach, though clinical success is not guaranteed and trials carry risk.
Data-driven value
Share price sensitivity is often linked to trial readouts and regulatory milestones; positive results can lift sentiment, but outcomes can vary.
Partnership potential
Collaborations or licensing deals could accelerate development and commercial reach, while financing needs and competition remain key considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
